New cocktail therapy aims to tackle Drug-Resistant lung cancer
NCT ID NCT07416058
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether a combination of the experimental drug QL1706, standard chemotherapy, and bevacizumab can shrink tumors in people with advanced non-squamous non-small cell lung cancer that has specific gene changes and has stopped responding to targeted therapy. About 61 participants will receive the treatment in 3-week cycles for up to 2 years. The main goal is to see if the tumor response rate improves compared to historical data.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QL1706 (a drug that targets PD-1 and CTLA-4), bevacizumab, pemetrexed, and platinum chemotherapy (cisplatin or carboplatin)
What this could lead to
If this works, it could offer a new treatment option for people with a specific type of lung cancer that has stopped responding to targeted therapy.
What could go wrong
This is a small, early-phase trial with no comparison group, so results may not be definitive. The combination of multiple drugs also increases the risk of side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••